- Home
- MTA vs DNA Comparison
MTA vs DNA Comparison
Compare MTA & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTA
- DNA
- Stock Information
- Founded
- MTA 1983
- DNA 2008
- Country
- MTA Canada
- DNA United States
- Employees
- MTA N/A
- DNA N/A
- Industry
- MTA
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MTA
- DNA Health Care
- Exchange
- MTA Nasdaq
- DNA Nasdaq
- Market Cap
- MTA 638.7M
- DNA 529.8M
- IPO Year
- MTA N/A
- DNA N/A
- Fundamental
- Price
- MTA $7.24
- DNA $9.17
- Analyst Decision
- MTA Hold
- DNA Strong Sell
- Analyst Count
- MTA 1
- DNA 1
- Target Price
- MTA $7.50
- DNA $9.00
- AVG Volume (30 Days)
- MTA 499.9K
- DNA 1.3M
- Earning Date
- MTA 11-13-2025
- DNA 11-06-2025
- Dividend Yield
- MTA N/A
- DNA N/A
- EPS Growth
- MTA N/A
- DNA N/A
- EPS
- MTA N/A
- DNA N/A
- Revenue
- MTA $10,546,000.00
- DNA $180,606,000.00
- Revenue This Year
- MTA $117.14
- DNA N/A
- Revenue Next Year
- MTA $69.62
- DNA $14.41
- P/E Ratio
- MTA N/A
- DNA N/A
- Revenue Growth
- MTA 108.91
- DNA N/A
- 52 Week Low
- MTA $2.45
- DNA $5.00
- 52 Week High
- MTA $7.73
- DNA $17.58
- Technical
- Relative Strength Index (RSI)
- MTA 59.50
- DNA 42.97
- Support Level
- MTA $6.42
- DNA $7.36
- Resistance Level
- MTA $7.09
- DNA $8.54
- Average True Range (ATR)
- MTA 0.33
- DNA 0.65
- MACD
- MTA 0.02
- DNA 0.14
- Stochastic Oscillator
- MTA 93.69
- DNA 55.62
About MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.